» Articles » PMID: 38291404

IL13Rα2 As a Crucial Receptor for Chi3l1 in Osteoclast Differentiation and Bone Resorption Through the MAPK/AKT Pathway

Overview
Publisher Biomed Central
Date 2024 Jan 30
PMID 38291404
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Previous research has revealed that the 18 glycoside hydrolase gene family (GH18) member Chitinase 3-like 1 (Chi3l1) can regulate osteoclast differentiation and bone resorption. However, its downstream receptors and molecular mechanisms during osteoclastogenesis have yet to be elucidated.

Methods: Initially, we conducted a comprehensive investigation to evaluate the effects of recombinant Chi3l1 protein or Chi3l1 siRNA on osteoclast differentiation and the RANKL-induced MAPK/AKT signaling pathways. Moreover, we used immunofluorescence and immunoprecipitation assays to identify IL13Rα2 as the downstream receptor of Chi3l1. Subsequently, we investigated the impact of IL13Rα2 recombinant protein or IL13Rα2-siRNA on osteoclast differentiation and the associated signaling pathways. Finally, we performed in vivo experiments to examine the effect of recombinant IL13Rα2 protein in an LPS-induced mouse model of cranial osteolysis.

Results: Our findings highlight that the administration of recombinant Chi3l1 protein increased the formation of osteoclasts and bolstered the expression of several osteoclast-specific genes (TRAP, NFATC1, CTR, CTSK, V-ATPase d2, and Dc-STAMP). Additionally, Chi3l1 significantly promoted the RANKL-induced MAPK (ERK/P38/JNK) and AKT pathway activation, whereas Chi3l1 silencing inhibited this process. Next, using immunofluorescence and co-immunoprecipitation assays, we identified IL13Rα2 as the binding partner of Chi3l1 during osteoclastogenesis. IL13Rα2 recombinant protein or IL13Rα2-siRNA also inhibited osteoclast differentiation, and IL13Rα2-siRNA attenuated the RANKL-induced activation of the MAPK (ERK/P38/JNK) and AKT pathways, similar to the effects observed upon silencing of Chi3l1. Moreover, the promoting effect of recombinant Chi3l1 protein on osteoclastogenesis and the activation of the MAPK and AKT pathways was reversed by IL13Rα2 siRNA. Finally, recombinant LI13Rα2 protein significantly attenuated the LPS-induced cranial osteolysis and the number of osteoclasts in vivo.

Conclusions: Our findings suggested that IL13Rα2 served as a crucial receptor for Chi3l1, enhancing RANKL-induced MAPK and AKT activation to promote osteoclast differentiation. These findings provide valuable insights into the molecular mechanisms of Chi3l1 in osteoclastogenesis, with potential therapeutic implications for osteoclast-related diseases. Video Abstract.

Citing Articles

Chitinase-3 Like-Protein-1 Signature in Neurological Disorders: Emphasis on Stroke.

Mathias K, Machado R, Andrade N, Piacentini N, Martins C, Prophiro J J Mol Neurosci. 2025; 75(1):25.

PMID: 39976746 DOI: 10.1007/s12031-025-02311-0.


TRAF1 promotes osteoclastogenesis by enhancing metabolic adaptation to oxidative phosphorylation in an AKT-dependent manner.

Kang H, Peng R, Dong Y, Dong Y, Liao F, Zhu M Mol Ther. 2025; 33(3):933-949.

PMID: 39863932 PMC: 11897774. DOI: 10.1016/j.ymthe.2025.01.040.


Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications.

Mwale P, Hsieh C, Yen T, Jan J, Taliyan R, Yang C Mol Neurodegener. 2025; 20(1):7.

PMID: 39827337 PMC: 11742494. DOI: 10.1186/s13024-025-00801-8.


IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients.

Karamikheirabad M, Zhang J, Ahn A, Park H, Park S, Moon Y Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598436 PMC: 11597473. DOI: 10.3390/ph17111526.


Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.

Salembier R, De Haes C, Bellemans J, Demeyere K, Van Den Broeck W, Sanders N Breast Cancer Res. 2024; 26(1):63.

PMID: 38605414 PMC: 11007917. DOI: 10.1186/s13058-024-01815-8.

References
1.
Nishikawa K, Millis A . gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res. 2003; 287(1):79-87. DOI: 10.1016/s0014-4827(03)00069-7. View

2.
Xue Q, Chen L, Yu J, Sun K, Ye L, Zheng J . Downregulation of Interleukin-13 Receptor α2 Inhibits Angiogenic Formation Mediated by Chitinase 3-Like 1 in Late Atherosclerotic Lesions of apoE Mice. Front Physiol. 2021; 12:690109. PMC: 8327173. DOI: 10.3389/fphys.2021.690109. View

3.
Fusetti F, Pijning T, Kalk K, Bos E, Dijkstra B . Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem. 2003; 278(39):37753-60. DOI: 10.1074/jbc.M303137200. View

4.
Yeo I, Lee C, Han S, Yun J, Hong J . Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol Ther. 2019; 203:107394. DOI: 10.1016/j.pharmthera.2019.107394. View

5.
Veis D, OBrien C . Osteoclasts, Master Sculptors of Bone. Annu Rev Pathol. 2022; 18:257-281. DOI: 10.1146/annurev-pathmechdis-031521-040919. View